A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D)…
ATTD Brings Together Top Minds in Diabetes Research
Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.
Top Researchers Gather for the 17th ATTD Conference
This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50…
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin…
World-Renowned Researchers Gather at the Breakthrough T1D-nPOD Annual Meeting
Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with…
Bench to Bedside: Breakthrough T1D-nPOD Conference
Leading scientists will gather for the annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), held February…
T1D + Eating Disorders: A Key Breakthrough T1D Priority
Breakthrough T1D funded 3 projects to address eating disorders + T1D and a study that presents the risks of T1D…
What Drug Will Be the Next Tzield?
In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog…
Breakthrough T1D and ISPAD Announce 2023 Fellows
Breakthrough T1D and ISAPD announce the recipients of the 2023 fellowships. These fellowships will help bring the best in T1D…
